Pharmaceutical company says it is also examining using a higher dose of its existing vaccine against new strain

Vaccine maker says it will soon share interim results of study with FDA and global regulators

Stephane Bancel says COVID shots will be okayed for infants and there will be enough doses by mid-2022 to inoculate everyone worldwide; thinks situation could come to resemble flu

Accumulating research suggests vaccine's superiority, possibly due to dosage level -- 100 micrograms against 30 -- or dosage interval, with Pfizer given 3 weeks apart and Moderna 4

Mayo Clinic research finds both inoculations have dropped in efficacy, but Pfizer's decline has been much steeper; both remain highly effective against severe illness

But pharma CEO warns that Delta variant of coronavirus 'is a significant new threat,' though booster candidates show efficacy against mutation

Tal Zaks 'hooded' at ceremony on campus, expresses confidence that vaccines will be able to counter variations of the coronavirus

Pfizer CEO echoes Netanyahu, UK authorities in saying strains of coronavirus likely to remain around indefinitely

Health body previously gave similar recommendation on Pfizer-BioNTech shot, a position rejected by Israel amid a spike in serious cases

Biotech firm says it is nonetheless testing whether adding a second booster, to make 3 shots in total, could increase protection from new strains